Scientific Doubts Over New Alzheimer's Drugs Pressure Major Pharma Stocks

A new scientific report has cast significant doubt on the clinical efficacy of Leqimbi and Kisunla, treatments previously hailed as breakthroughs in the fight against Alzheimer's disease. The report suggests that the actual impact of these drugs on slowing cognitive decline may be less substantial than initially marketed to investors and patients. Pharmaceutical giants Biogen, Eli Lilly, and Eisai are now facing increased scrutiny as the scientific reality proves more complex than expected. Analysts warn that these findings could lead to insurance coverage hurdles and lower clinical adoption rates, putting downward pressure on stock valuations. The market is closely monitoring how health authorities will respond to this data, which could redefine the commercial potential of these high-priced therapies.